Valensa wins eye health gong

- Last updated on GMT

Related tags: Eye health, Macular degeneration, Nutrition, Retina

Frost & Sullivan has handed Valensa an award for developing the global eye health market for astaxanthin, highlighting formulation and patent innovation as key points of success.

Frost analyst Sneha Pasricha drew comparisons between astaxanthin and lutein, which is more widely recognized as an eye health nutrient

"Owing to astaxanthin's higher antioxidant capacity compared to that of lutein, and established by relevant tests, diseases such as age-related macular degeneration, cataracts, retinal, arterial, and venous occlusion, diabetic retinopathy, and depth perception issues are expected to be mitigated by fewer per-day doses of astaxanthin compared to that of lutein,"​ Pasricha said.

Valensa president and chief executive officer Dr Rudi E Moerck said the award would help raise the profile of astaxanthin.

While Frost has acknowledged the scientific backing of the eye health benefits of lutein and astaxanthin, the European Food safety Authority (EFSA) has not, issuing negative opinions for eye, joint and other benefits in the past six months to both nutrients.

But players in the sector say they are resubmitting claims under the highly complicated and controversial process that has seen few health claim submissions draw positive opinions.

Related topics: Suppliers

Related news

Follow us

Featured Events

View more

Products

View more

Webinars